Celularity Inc. Form 8-K Summary
Filing date: September 15, 2022. The filing reports Celularity’s entry into a material financing agreement and creation of related financial obligations. It does not provide quarterly or annual operating results.
Financing and Key Terms
- Celularity entered into a Pre-Paid Advance Agreement with YA II PN, Ltd., an investment vehicle managed by Yorkville.
- Celularity received an initial $40.0 million pre-paid advance, reduced by a 2.0% discount to $39.2 million in cash, before other applicable costs.
- Additional advances of up to $40.0 million may be requested over an 18-month period, subject to mutual agreement, with an aggregate limitation of $150.0 million unless the parties agree otherwise.
- Advances bear interest at 6.0% annually, increasing to 15.0% upon specified defaults. Celularity also paid a $10,000 structuring and due diligence fee.
- Yorkville may use advances to purchase Celularity Class A common stock at the lower of a formula-based fixed price or 95% of the lowest applicable three-day VWAP, subject to a floor price of $0.75 per share.
- Shares issued under the agreement are subject to a 19.9% aggregate issuance cap based on Celularity’s outstanding stock as of September 15, 2022, and Yorkville’s 4.99% beneficial ownership limitation.
- Yorkville agreed not to purchase shares for 60 days after signing and generally may not purchase more than $6.0 million of shares during any 30-day period at a price below the fixed price.
Material Changes, Obligations, and Risks
- The agreement provides near-term liquidity but creates interest-bearing obligations and potential future equity dilution.
- If the daily VWAP falls below $0.75 for any five of seven consecutive trading days, or substantially all shares under the 19.9% cap are issued, Celularity must make monthly cash payments of $6.0 million, plus accrued interest and a 5.0% redemption premium, until specified share-price conditions are met.
- The arrangement therefore exposes Celularity to significant repayment and cash-flow risk if its stock price remains below the applicable threshold.
- Celularity must maintain its Form S-3 shelf registration statement, register the shares issuable to Yorkville, use proceeds as disclosed in applicable prospectus supplements, and generally avoid other variable-rate transactions except as permitted by the agreement.
- The filing does not disclose the company’s cash balance, revenue, profitability, operating cash flow, debt balances before this transaction, or stated management guidance.
Investor Verification Items
- Verify the executed Pre-Paid Advance Agreement and all conditions governing additional advances, defaults, repayment, and redemption.
- Review the related prospectus supplement and Form S-3 registration statement for intended use of proceeds and potential share issuance.
- Monitor shares issued to Yorkville against the 19.9% issuance cap and the 4.99% beneficial ownership limitation.
- Assess whether Celularity’s available cash and expected operating cash flow can support potential $6.0 million monthly payments and other obligations.
- Confirm the accounting treatment, carrying value, interest expense, and classification of the pre-paid advance in subsequent financial statements.